Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David N. Louis, M.D.

Co-Author

This page shows the publications co-authored by David Louis and Keith Ligon.
Connection Strength

0.951
  1. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 2007 Feb 15; 53(4):503-17.
    View in: PubMed
    Score: 0.091
  2. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol. 2006 Dec; 65(12):1149-56.
    View in: PubMed
    Score: 0.089
  3. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol. 2005 Nov; 64(11):948-55.
    View in: PubMed
    Score: 0.083
  4. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. 2004 May; 63(5):499-509.
    View in: PubMed
    Score: 0.075
  5. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26.
    View in: PubMed
    Score: 0.060
  6. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 08 08; 178(4):835-849.e21.
    View in: PubMed
    Score: 0.054
  7. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335.
    View in: PubMed
    Score: 0.049
  8. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
    View in: PubMed
    Score: 0.046
  9. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.041
  10. Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
    View in: PubMed
    Score: 0.041
  11. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6.
    View in: PubMed
    Score: 0.038
  12. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb; 46(2):161-5.
    View in: PubMed
    Score: 0.037
  13. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9.
    View in: PubMed
    Score: 0.034
  14. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98.
    View in: PubMed
    Score: 0.033
  15. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun; 14(6):761-7.
    View in: PubMed
    Score: 0.033
  16. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59.
    View in: PubMed
    Score: 0.030
  17. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948.
    View in: PubMed
    Score: 0.030
  18. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res. 2009 Oct 15; 15(20):6430-7.
    View in: PubMed
    Score: 0.027
  19. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 01; 21(21):2683-710.
    View in: PubMed
    Score: 0.024
  20. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006 Dec 01; 66(23):11502-13.
    View in: PubMed
    Score: 0.022
  21. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2002 Apr; 1(3):269-77.
    View in: PubMed
    Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.